-continued

Formula 5



Formula 6



Formula 7



10. The method of claim **9**, wherein the PKCδI inhibitor is effective to reduce PKCδI activity in the subject in need thereof.

11. The method of claim **9**, wherein the PKCδI inhibitor is effective to reduce PKCδI activity in an adipocyte in the subject in need thereof.

12. The method claim **9**, wherein the PKCδI inhibitor is a compound according to Formula 1

Formula 1



13. The method of claim **9**, wherein the PKCδI inhibitor is effective to reduce the activity of PKCδI and is not effective to reduce the activity of PKCα, PKCβ, PKCγ, PKCε, PKCθ, PKCI, PKCζ PKCδII, PKCδIII or any combination thereof.

14. The method of claim **9**, wherein the PKCδI inhibitor simultaneously binds the DMQD amino acid sequence within the V3 hinge region of PKCδI and the active site on the C2 domain of PKCδI.

15. The method of claim **9**, wherein the subject in need thereof has diabetes, a cancer, an inflammatory, disease obesity, insulin resistance, metabolic syndrome hepatosteatosis, a cardiovascular disease, a neurodegenerative disease or a symptom thereof.

16.-**24**. (canceled)

25. A method of reducing PKCδI expression in a subject in need thereof, the method comprising:

administering a formulation comprising an effective amount of a PKCδI inhibitor to the subject in need thereof, wherein the PKCδI inhibitor is a compound having a structure as in Formula 1

Formula 1



or a structural analogue thereof, wherein the structural analogue specifically binds the DMQD amino acid sequence within the V3 hinge region of PKCδI or simultaneously bind the DMQD amino acid sequence within the V3 hinge region of PKCδI and the active site of PKCδI on the C2 domain of PKCδI.

26. The method of claim **25**, wherein PKCδI expression is reduced in an adipocyte in a subject in need thereof.

27. The method of claim **25**, wherein the PKCδI inhibitor is effective to reduce activity of PKCδI and is not effective to reduce the activity of PKCα, PKCβ, PKCγ, PKCε, PKCδ, PKCI, PKCζ PKCδII, PKCδVIII or any combination thereof.

28. The method of claim **25**, wherein the subject in need thereof has a PKCδI disorder.

29. The method of claim **25**, wherein the subject in need thereof has diabetes, a cancer, an inflammatory, disease obesity, insulin resistance, metabolic syndrome hepatosteatosis, a cardiovascular disease, a neurodegenerative disease or a symptom thereof.

* * * * *